title: Antiviral activity of 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy] guanine against cytomegalovirus and herpes simplex virus.
abstract: An isosteric analog of 9-[2-(phosphonomethoxy)ethyl]guanine (PMEG), 9-[[(ethoxyhydroxyphosphinyl)methoxy]methoxy]guanine (SKI 1008), was evaluated for its in vitro antiviral activity against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), murine cytomegalovirus (MCMV), and human cytomegalovirus (HCMV), and its in vivo antiviral efficacy against MCMV in mice. The in vitro anti-HSV activity of SKI 1008 was much lower than that of acyclovir, even though SKI 1008 showed similar antiviral activity against thymidine kinase positive (TK+) and thymidine kinase negative (TK-) strains. Like ganciclovir and PMEG, SKI 1008 selectively inhibited plaque formation of MCMV; the 50% effective concentration (EC50) and the 50% cytotoxic concentration (CC50) of SKI 1008, ganciclovir, and PMEG being 0.51 and 600, 1.65 and 461, and 0.06 and 12.1 micrograms/ml, respectively. The in vitro EC50 value of SKI 1008 against HCMV was comparable to that of ganciclovir (0.24 vs 0.16 microgram/ml) and was 12-fold higher than that of PMEG in a plaque reduction assay, but the therapeutic indices (the ratios of CC50 to EC50) of SKI 1008 and ganciclovir were higher than that of PMEG. The in vivo antiviral efficacy of SKI 1008 in MCMV-infected normal BALB/c and severe combined immunodeficiency (SCID) mice was lower than that of ganciclovir in terms of mortality and mean survival time.
authors.affiliation: Life Science Research Center, Sunkyong Industries, Suwon-Si, Kyungki-Do, Korea.
authors.forename: H T
authors.initials: HT
authors.lastname: Kim
authors.forename: D K
authors.initials: DK
authors.lastname: Kim
authors.forename: Y W
authors.initials: YW
authors.lastname: Kim
authors.forename: K H
authors.initials: KH
authors.lastname: Kim
authors.forename: Y
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: M
authors.initials: M
authors.lastname: Kikuchi
mesh_terms: D000212:Acyclovir / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000187:drug effects*; D015774:Ganciclovir / Q000494:pharmacology / Q000627:therapeutic use; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006566:Herpesviridae Infections / Q000188:drug therapy*; D018259:Herpesvirus 1, Human / Q000187:drug effects*; D018258:Herpesvirus 2, Human / Q000187:drug effects; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D016513:Mice, SCID; D018146:Muromegalovirus / Q000187:drug effects; D013047:Specific Pathogen-Free Organisms
chemical_list: D000998:Antiviral Agents; C099444:9-(((ethoxyhydroxyphosphinyl)methoxy)methoxy)guanine; D006147:Guanine; D015774:Ganciclovir; D000212:Acyclovir